$CGEN
HOLON, Israel, Jan. 14, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, will be featured in a trial-in-progress poster at The ASCO-SITC Clinical Immuno-Oncology Symposium, taking place February 28-March 2, 2019, in San Francisco, CA
September 30, 2018
------------------------
Total current assets - 44,490K$
Net loss for 3M - 3,111K$
A low risk for Offering before ASCO-SITC Clinical Immuno-Oncology Symposium.
------------------------
Technically
--------------
support at 3.29 (Possibility for a bullish flag pattern)
In today Avg 3.41 (Second cycle)
Not for any suggestion - very risky.
September 30, 2018
------------------------
Total current assets - 44,490K$
Net loss for 3M - 3,111K$
A low risk for Offering before ASCO-SITC Clinical Immuno-Oncology Symposium.
------------------------
Technically
--------------
support at 3.29 (Possibility for a bullish flag pattern)
In today Avg 3.41 (Second cycle)
Not for any suggestion - very risky.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.